Opinion

Video

Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in the frontline setting, by offering effective, targeted therapy that provides significant clinical benefits and improves overall survival compared with traditional chemotherapy.

  1. How have BTK inhibitors transformed the treatment paradigm for patients with CLL and MCL, particularly in the frontline setting?
Related Videos
3 experts are featured in this series.
5 experts are featured in this series
4 experts are featured in this series.
4 experts are featured in this series.
5 experts are featured in this series
1 expert is featured in this series.
3 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo